FY22 - APA buildings - building 2
Active Awarded Last action
- Contract number
- 75N91022F00028
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,180,966
Award facts
- Contract value 100% obligated
- $6,180,966.00 Current and potential, with all options
- Completion date 93% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$221,800 | |
| Terminate for Convenience | $0 | |
| Supplemental Agreement for work within scope | $694,653 | |
| Other Administrative Action | $0 | |
| Original award | $5,708,113 |
About this award
The National Cancer Institute awarded a delivery order contract to Leidos Biomedical Research Inc. valued at $6.18 million for FY22 APA Buildings—Building 2 improvements at the Frederick, Maryland facility. This cost-plus-fixed-fee delivery order, issued on September 20, 2022, with an ultimate completion date of February 5, 2027, was not designated under any small business set-aside program. Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., operates as a Federally Funded Research and Development Center (FFRDC) contractor primarily supporting the NCI and National Institutes of Health, providing comprehensive biomedical research and facilities support services.
The contract supports critical infrastructure improvements at the Frederick National Laboratory for Cancer Research, where Leidos delivers advanced research capabilities spanning medical research, clinical trials, facility management, and specialized laboratory services. As an established FFRDC contractor, Leidos has demonstrated extensive experience executing multi-year, cost-plus-fixed-fee contracts involving complex scientific and technical operations. The company's scope under this delivery order likely encompasses facilities maintenance, infrastructure upgrades, and operational support necessary to sustain the laboratory's mission in cancer research and related biomedical investigations across diverse scientific domains.
Quick answers
Who was awarded contract 75N91022F00028?
75N91022F00028 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 20, 2022.
How much is contract 75N91022F00028 worth?
The government has obligated $6,180,966 on 75N91022F00028.
Is contract 75N91022F00028 an order under another contract?
Yes. 75N91022F00028 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91022F00028 competed?
The extent of competition for 75N91022F00028 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award